Ebola

Protecting patients and their families from the devastating effects of Ebola is a national priority.

Stopping the spread of Ebola will require close collaboration and engagement from stakeholders across the health care system, and the biopharmaceutical industry stands ready to do its part to assist patients and their families affected by this terrible virus. Over the past several years, biopharmaceutical researchers have been working to develop vaccines and treatments to prevent infection and fight its effects, and there are at least two Ebola vaccines currently in the pipeline.

Five Things You Might Not Know About Medicare Part D

10.15.14 | By

Another Medicare open enrollment period begins today, Wednesday, October 15, and runs through Sunday, December 7. During open enrollment seniors and individuals with disabilities can evaluate their Medicare plan choices to make sure they’re still right for them, compare options and make changes for the new year. One thing beneficiaries evaluate during open enrollment is their prescription drug coverage. Here are five things you might not know about Medicare Part D:

Week in Review: Innovation and the Promise of Hope

10.10.14 | By

We often use the word “innovation” in Catalyst posts and on social media. To many, “innovation” may seem like just another buzzword, but to the biopharmaceutical industry it is the definition of hope. It is the hope that we can help patients live longer and healthier lives through, in large part, the development of new treatments.

Why Are Cancer Medicines Expensive?

10.06.14 | By

This post first appeared on the Morning Consult. For more on the 771 medicines in development to treat or prevent cancer, check out our latest report.

When It Comes to Getting Your Meds, Are You Covered?

10.01.14 | By

Four in five American adults take at least one medication, and more than one in four take five medicines or more. For patients to live longer, healthier lives, being able to access needed treatments is critical. Not to mention, adhering to treatment regimens can help prevent costly and burdensome complications down the road.

What the NY Times Got Wrong About Biopharmaceutical Innovation

07.24.14 | By

A recent article in the New York Times once again missed the mark when it comes to reporting on the great promise in the biopharmaceutical pipeline.

Oncology By the Numbers Graphic

PhRMA Statement on Sustainability & Manufacturing Process

Washington, D.C. (April 23, 2009) — Pharmaceutical Research and Manufacturers of America Senior Vice President Ken Johnson issued the following statement today in response to recent media attention surrounding pharmaceutical ingredients discharged by manufacturing facilities:

“Recent public concern about media reports of traces of medicines in the water deserves some clarification of the role America’s pharmaceutical companies play in fostering sustainable manufacturing practices as part of their goal of delivering new medicines to patients.

Test White Papers

03.22.13 | By phrma_admin
Subscribe to RSS - Medicines